Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 16;7(2):185-198.
eCollection 2021 Apr 22.

Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer

Sara Montemuiño Muñiz  1 , Soraya Marcos Sánchez  1 , Julia Calzas Rodríguez  2 , Beatriz Losada Vila  2 , Esther Llorente Herrero  3 , María Dolores Hisado Díaz  4 , Victoria Valeri-Busto González  4 , Begoña Taboada Valladares  5 , Blanca Vaquero Barrón  6 , Francisco José Marcos Jimenez  7 , Sergio Amor Alonso  8 , Javier Moradiellos  8 , Núria Rodríguez de Dios  9   10   11 , Felipe Couñago  12   13   14
Affiliations
Review

Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer

Sara Montemuiño Muñiz et al. J Clin Transl Res. .

Abstract

Background and aim: In Stage IIIA-N2 non-small cell lung cancer (NSCLC), the accuracy of combined positron-emission tomography/computed tomography imaging (PET-CT), together with mediastinal staging techniques, has led to a wide range of challenging clinical scenarios in terms of therapeutic management. Concurrent chemoradiotherapy followed by consolidation immunotherapy remains the standard of care. In patients with potentially-resectable disease, surgery plays an important role in multimodal therapy. The introduction of targeted therapies and immune-checkpoint inhibitors has revolutionized multimodal treatment. In the present article, we review current treatment options and future trends in stage IIIA-N2 NSCLC.

Relevance for patients: This article provides insight into the current status of multimodal treatment for NSCLC to support decision-making in routine clinical practice.

Keywords: chemoradiation; immunotherapy; neoadjuvant treatment; non-small cell lung cancer; stage IIIA; surgery.

PubMed Disclaimer

Conflict of interest statement

The authors indicate no potential conflicts of interest.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2020. CA Cancer J Clin. 2020;70:7–30. - PubMed
    1. Reck M, Rabe KF. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377:849–61. - PubMed
    1. Rami-Porta R, Asamura H, Travis WD, Rusch VW. Lung Cancer - Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. CA Cancer J Clin. 2017;67:138–55. - PubMed
    1. Vilmann P, Clemensten PF, Colella S, Siemsen M, De Leyn P, Dumonceau JM, et al. Combined Endobronchial and Oesophageal Endosonography for the Diagnosis and Staging of Lung Cancer. Eur Respir J. 2015;46:40–60. - PubMed
    1. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2010;28:2181–90. - PubMed

LinkOut - more resources